Yes, but Dapto's patent is expiring in 2016 and that doesn't make it the most valuable asset next year. My point is we all keep hammering that Merck was buying Cubist for $9.5 billions because of Dapto. But I think Merck sees more than that because Cubist have other antibiotics as well. Bottom line, say it whatever you want, if we really worth $9.5 billion next year (assuming CTIX passed B-ABSSSI PH3 trials), then the question is why are we still sitting at $163.53 million (not even half a billion)? When Cubist was acquired, the company's market cap is already about $6 billions.